Market Research Report
Atypical Hemolytic Uremic Syndrome - Pipeline Review, H2 2019
|Published by||Global Markets Direct||Product code||321898|
|Published||Content info||104 Pages
Delivery time: 1-2 business days
|Atypical Hemolytic Uremic Syndrome - Pipeline Review, H2 2019|
|Published: August 30, 2019||Content info: 104 Pages||
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atypical Hemolytic Uremic Syndrome - Pipeline Review, H2 2019, provides an overview of the Atypical Hemolytic Uremic Syndrome (Gastrointestinal) pipeline landscape.
Atypical hemolytic uremic syndrome is a disease that primarily affects kidney function. This condition, which can occur at any age, causes abnormal blood clots (thrombi) to form in small blood vessels in the kidneys. Symptoms include vomiting, abdominal pain, pale skin tone, fatigue and irritability, blood in the urine and confusion.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Atypical Hemolytic Uremic Syndrome - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Atypical Hemolytic Uremic Syndrome (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Atypical Hemolytic Uremic Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 1, 3 and 5 respectively.
Atypical Hemolytic Uremic Syndrome (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.